BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stock Short Interest Rises 74.0%

BioNexus Gene Lab Corp. (NASDAQ:BGLC) saw a large growth in short interest in September. As of September 15th, there was short interest totaling 13,030 shares, a growth of 74.0% from the August 31st total of 7,488 shares. Based on an average daily trading volume, of 3,712 shares, the short-interest ratio is currently 3.5 days. Currently, 0.4% of the shares of the stock are short sold.

BioNexus Gene Lab Price Performance

BGLC stock opened at $1.22 on Thursday. The stock has a market cap of $3.57 million, a price-to-earnings ratio of -0.97 and a beta of 4.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.08 and a quick ratio of 5.28. The company has a 50 day simple moving average of $1.48 and a 200 day simple moving average of $1.92. BioNexus Gene Lab has a 1 year low of $1.07 and a 1 year high of $5.89.

BioNexus Gene Lab (NASDAQ:BGLC) last issued its earnings results on Friday, August 14th. The company reported ($0.12) earnings per share for the quarter. The company had revenue of $0.08 million during the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative return on equity of 32.92%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About BioNexus Gene Lab

BioNexus Gene Lab Corp. (NASDAQ:BGLC) is a biotechnology and molecular diagnostics company focused on developing genetic tests intended to support the early detection of cancer and other diseases. Its diagnostic work uses blood-based and molecular analysis to identify biological indicators that may help healthcare providers assess disease risk and guide further evaluation.

The company operates through two primary business areas: Molecular Diagnostics and Chemical Trading. The Molecular Diagnostics segment develops and commercializes genetic testing products, while the Chemical Trading segment distributes industrial chemicals and related products to customers in its served markets.

BioNexus Gene Lab is headquartered in Kuala Lumpur, Malaysia, and its operations have included activities in the Malaysian market.